SGAM
Smith Group Asset Management Portfolio holdings
AUM
$1.53B
1-Year Return
38.67%
This Quarter Return
+16.87%
1 Year Return
+38.67%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$3.09B
AUM Growth
+$251M
(+8.8%)
Cap. Flow
-$137M
Cap. Flow
% of AUM
-4.46%
Top 10 Holdings %
Top 10 Hldgs %
29.06%
Holding
490
New
44
Increased
77
Reduced
236
Closed
43
Top Buys
| 1 |
Palo Alto Networks
PANW
|
$63.7M |
| 2 |
Dover
DOV
|
$30.2M |
| 3 |
Expeditors International
EXPD
|
$27.8M |
| 4 |
Deckers Outdoor
DECK
|
$27.6M |
| 5 |
Procter & Gamble
PG
|
$27.2M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$40.1M |
| 2 |
Home Depot
HD
|
$39.1M |
| 3 |
Apple
AAPL
|
$36.6M |
| 4 |
Adobe
ADBE
|
$35.5M |
| 5 |
Allison Transmission
ALSN
|
$34.1M |
Sector Composition
| 1 | Technology | 30.47% |
| 2 | Consumer Discretionary | 14.74% |
| 3 | Industrials | 14.02% |
| 4 | Healthcare | 13.44% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Sierra Bancorp
BSRR
$412M
| $75K | ﹤0.01% |
3,105
-180
| -5% | -$4.35K |
|
|
IMMU
277
DELISTED
Immunomedics Inc
IMMU
| $74K | ﹤0.01% |
3,870
-11,100
| -74% | -$212K |
|
|
CEO
278
DELISTED
CNOOC Limited
CEO
| $72K | ﹤0.01% |
390
+20
| +5% | +$3.69K |
|
|
ICPT
279
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $70K | ﹤0.01% |
630
-2,200
| -78% | -$244K |
|
|
EGRX
280
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $69K | ﹤0.01% |
1,372
-80
| -6% | -$4.02K |
|
|
PTLA
281
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $69K | ﹤0.01% |
1,990
-5,600
| -74% | -$194K |
|
282
Amicus Therapeutics
FOLD
$2.46B
| $67K | ﹤0.01% |
4,960
-16,000
| -76% | -$216K |
|
283
Insmed
INSM
$30.7B
| $67K | ﹤0.01% |
+2,310
| New | +$67K |
|
284
Shoe Carnival
SCVL
$673M
| $66K | ﹤0.01% |
3,860
-240
| -6% | -$4.1K |
|
285
ENI
E
$51.3B
| $64K | ﹤0.01% |
1,820
+1,520
| +507% | +$53.5K |
|
286
Halozyme
HALO
$8.76B
| $64K | ﹤0.01% |
3,980
-12,400
| -76% | -$199K |
|
287
Petrobras
PBR
$78.7B
| $64K | ﹤0.01% |
4,017
+170
| +4% | +$2.71K |
|
288
Wells Fargo
WFC
$253B
| $60K | ﹤0.01% |
1,240
+40
| +3% | +$1.94K |
|
289
Citigroup
C
$176B
| $59K | ﹤0.01% |
950
-50
| -5% | -$3.11K |
|
290
Myriad Genetics
MYGN
$615M
| $59K | ﹤0.01% |
1,790
-5,500
| -75% | -$181K |
|
|
RUTH
291
DELISTED
Ruth's Hospitality Group, Inc.
RUTH
| $58K | ﹤0.01% |
2,278
-130
| -5% | -$3.31K |
|
292
Heron Therapeutics
HRTX
$201M
| $56K | ﹤0.01% |
2,310
-6,600
| -74% | -$160K |
|
293
Ironwood Pharmaceuticals
IRWD
$188M
| $56K | ﹤0.01% |
4,979
-14,447
| -74% | -$162K |
|
294
PTC Therapeutics
PTCT
$4.55B
| $55K | ﹤0.01% |
1,460
-3,900
| -73% | -$147K |
|
|
BF
295
DELISTED
BASF AKTIENGESELLT ADS(RP1 ORD
BF
| $55K | ﹤0.01% |
2,980
+1,340
| +82% | +$24.7K |
|
|
ARNA
296
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $52K | ﹤0.01% |
1,170
-4,200
| -78% | -$187K |
|
297
Enanta Pharmaceuticals
ENTA
$189M
| $50K | ﹤0.01% |
520
-1,300
| -71% | -$125K |
|
298
AnaptysBio
ANAB
$613M
| $46K | ﹤0.01% |
630
-1,700
| -73% | -$124K |
|
299
Ovintiv
OVV
$10.6B
| $46K | ﹤0.01% |
1,264
+534
| +73% | +$19.4K |
|
300
Sasol
SSL
$4.51B
| $46K | ﹤0.01% |
1,490
+60
| +4% | +$1.85K |
|